ConductScience.org, home

Paper5081602

Daunorubicin metabolism in acute nonlymphocytic leukemia.

Huffman DH and 2 others. Clin Pharmacol Ther, 1972. Cited by 95 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Daunorubicin metabolism in acute nonlymphocytic leukemia. Papers, record 5081602. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/5081602

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Daunorubicin metabolism in acute nonlymphocytic leukemia.
PubMed
Journal
Clin Pharmacol Ther
PubMed
Year
1972
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
95
iCite
Relative citation ratio, by iCite
3.74
iCite
Revised in PubMed
2019-05-11
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Huffman DHD H
2Benjamin RSR S
3Bachur NRN R

Source PubMed

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DaunorubicinMajor topic
LeukemiaMajor topic
Adipose Tissue
Chromatography, Thin Layer
Half-Life
Humans
Injections, Intravenous
Kidney
Liver
Lung
Muscles
Myocardium
Pancreas
Spectrometry, Fluorescence
Spleen

Source PubMed

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 95 citations.

PMIDTitleJournalYearIn PapersSource
34,689,693The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients.Leuk Lymphoma2022https://conductscience.org/library/papers/34689693PubMed
20,861,736Pharmacogenomics in pediatric leukemia.Curr Opin Pediatr2010https://conductscience.org/library/papers/20861736PubMed
12,882,589Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia.Clin Pharmacokinet2003https://conductscience.org/library/papers/12882589PubMed
7,860,226Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome).Invest New Drugs1994https://conductscience.org/library/papers/7860226PubMed
7,459,213Heparin does not modify plasma daunomycin disappearance in acute leukaemia patients.Br J Cancer1980https://conductscience.org/library/papers/7459213PubMed
7,261,253Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients.Cancer Chemother Pharmacol1981https://conductscience.org/library/papers/7261253PubMed
6,189,661Clinical pharmacokinetics of commonly used anticancer drugs.Clin Pharmacokinet1983https://conductscience.org/library/papers/6189661PubMed
4,524,632Adriamycin and daunorubicin inhibition of mutant T4 DNA polymerases.Proc Natl Acad Sci U S A1974https://conductscience.org/library/papers/4524632PubMed
3,891,121Uptake and metabolism of daunorubicin by human myelocytic cells.Cancer Chemother Pharmacol1985https://conductscience.org/library/papers/3891121PubMed
3,600,054Plasma levels of daunorubicin metabolites and the outcome of ANLL therapy.Med Oncol Tumor Pharmacother1987https://conductscience.org/library/papers/3600054PubMed
3,471,265Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer.Br J Clin Pharmacol1987https://conductscience.org/library/papers/3471265PubMed
1,760,856Use of plasma cytotoxic activity to model cytotoxic pharmacodynamics of anticancer drugs.Cancer Chemother Pharmacol1991https://conductscience.org/library/papers/1760856PubMed
1,107,513Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.J Pharmacokinet Biopharm1975https://conductscience.org/library/papers/1107513PubMed
799,549Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure.Clin Pharmacokinet1976https://conductscience.org/library/papers/799549PubMed
535,134Human pharmacokinetics of the daunorubicin-DNA complex. An alternative view of the lysosomotropic theory.Cancer Chemother Pharmacol1979https://conductscience.org/library/papers/535134PubMed
498,413Liquid chromatographic monitoring of daunorubicin and daunorubicinol in plasma from leukemic patients treated with daunorubicin or the daunorubicin-DNA complex.Cancer Chemother Pharmacol1979https://conductscience.org/library/papers/498413PubMed
119,583Comparative metabolism and excretion of adriamycin in man, monkey, and rat.Cancer Chemother Pharmacol1979https://conductscience.org/library/papers/119583PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/5081602

GET https://conductscience.org/api/papers/v1/5081602/authors